Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS5626 in Participants With Non-segmental Vitiligo
NCT07840820Phase 3Not yet recruiting
- Sponsor
- Fosun Pharma
- Start
- Oct 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 3 trial of FXS5626 in Vitiligo, sponsored by Fosun Pharma. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
FXS5626
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07840820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840820.